Drugs / Preladenant
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03099161 | Jun → Nov 2017 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01465412 | Nov 2011 → Jun 2012 | liver disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01323855 | Mar → Nov 2011 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00845000 | Apr 2009 → Apr 2010 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT01294800 | Feb 2011 → Jun 2013 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00537017 | Nov 2007 → Nov 2009 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00693472 | Aug 2007 → Dec 2008 | drug-induced akathisia, movement disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00406029 | Nov 2006 → Oct 2008 | Parkinson disease, movement disorder, neurodegenerative disease | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT00686699 | Jul 2006 → Mar 2008 | drug-induced akathisia, drug-induced dyskinesia, parkinsonian disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 34 trials · 3 missed | ||||||
| Phase 3 | NCT01227265 | Nov 2010 → Apr 2013 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT01215227 | Nov 2010 → Jul 2013 | Parkinson disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01155466 | Jul 2010 → Dec 2012 | Parkinson disease | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT01155479 | Jul 2010 → Jul 2013 | Parkinson disease | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-05-23 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine merck.com ↗
An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-05-23 | Merck Sharp & Dohme LLC | Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine merck.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | preladenant | “Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)” NCT00845000 ↗ |
| Known as | MK-3814 | ChEMBL registry synonym — accepted as the source's own label CHEMBL240624 ↗ |
| Known as | SCH 420814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00845000 ↗ |
| Action | Inhibit | “Preladenant is an adenosine 2A (A₂(A)) receptor antagonist.” PMID 21315654 ↗ Mar 20111“Adenosine A2a receptor antagonist” CHEMBL240624 ↗ |
| Modality | Small molecule | — CHEMBL240624 ↗ |
| Route | Oral | “Patients were assigned to receive 1, 2, 5, or 10 mg oral preladenant twice daily, or matching placebo for 12 weeks.” PMID 21315654 ↗ Mar 2011 |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL240624 ↗ |